Prolaio Pulse

Today, we’re excited to announce that Prolaio has been acquired by Kardigan, a heart health company modernizing cardiovascular (CV) drug development. This combination will enable us to accelerate the impact of our software and bring more effective, accessible cardiovascular treatments to patients around the world.

Many heart conditions share similar symptoms, yet their causes, risks, and treatments vary significantly. As a consequence of these similarities, misdiagnosis is common, making early and accurate diagnosis crucial for effective management and long-term heart health. Let’s explore what makes hypertrophic cardiomyopathy (HCM) unique and why recognizing it early can make all the difference.

Hypertrophic cardiomyopathy (HCM) is a complex heart condition that requires careful monitoring and management. While HCM presents unique challenges, advancements in technology offer innovative tools that can significantly improve the quality of life for individuals with this condition. Let's explore how technology is revolutionizing HCM management and draw inspiration from success stories in other areas of healthcare.

Hypertrophic cardiomyopathy (HCM) changes how we experience the holidays. In today's post, we talk with Mike Papale, a survivor of sudden cardiac arrest due to HCM. Topics include reflections on the holidays, progress in health policy, and how community collaboration could lead to the gift that everyone dealing with HCM wants, a normal life.